9:55 AM ET
Earnings Call
▶ Call
Iovance Biotherapeutics Earnings Call: Key Takeaways
Iovance delivered record Q3 revenue of $122 million and 60% margins, driven by strong Amtagvi adoption and a cash runway extended into 2029.
- Call
- Nov 5, 2026, 8:30 AM ET